No Data
Orient: Initiated a "Buy" rating for Hutchmed (China) with a Target Price of HKD 33.24.
Orient issued a research report predicting that Hutchmed (China) (00013) will have revenue of 680 million, 844 million, and 1 billion USD for 2024-2026, respectively. Based on comparable companies, a 4.4 times PS is given for the company in 2025, corresponding to a Target Price of 33.24 HKD, with an initial 'Buy' rating. Orient's main points are as follows: a Global layout of small molecule Innovative Drugs. The company was founded in 2000, and after more than twenty years of deep cultivation in the small molecule oncology field, it has three commercialized products and several late-stage clinical drugs, accumulating rich experience in commercial Operation, and partnering with...
Express News | Orient Securities Co - Lu Weiming Will No Longer Serve as President
Sinolink: With the dual benefit of policy bullish and warming funds, the Brokerage sector is expected to see an increase in both valuation and performance.
Sinolink released a Research Report stating that looking ahead to 2025, liquidity is expected to further ease, enhancing market stability and building a solid market bottom. The improvement in economic fundamentals is confirmed, and the stock market is likely to rise further, which is Bullish for the valuation and performance of the Brokerage Sector.
Hong Kong stocks fluctuate | China-affiliated brokerage stocks rise broadly in early trading. Key meetings further clarify the stability of the stock market, with bullish trends in both stocks and bonds benefiting the brokerage sector.
China-affiliated brokerage stocks rose broadly in the morning session. As of the time of writing, gf sec (01776) rose 4.31%, trading at 12.1 HKD; swhy (03678) rose 3.8%, trading at 3.28 HKD; htsc (06886) rose 2.92%, trading at 14.8 HKD; china merchants (06099) rose 1.67%, trading at 18.28 HKD.
Orient Securities Company Limited (SHSE:600958) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Orient maintains a "buy" rating on Meituan-W with a target price of 215.76 Hong Kong dollars.
Orient Securities published a research report stating to maintain Meituan-W (03690) "buy" rating, considering the resilience of Meituan's business in the macroeconomic environment, the core local business synergy effect is expected to be released, and new business progress is good. The company's eps for 2024-2026 is adjusted to 6.42/7.65/9.26 yuan (originally 6.15/7.43/8.21 yuan for 2024-2026), with a target price of 215.76 Hong Kong dollars. The company's Q3 2024 revenue is 93.6 billion yuan (yoy +22.4%), with adjusted operating profit of 13.6 billion yuan and an operating margin of 14.5%, overall performance exceeding expectations.
